[A22-124] Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67
Last updated 05.01.2023
Project no.:
A22-124
Commission:
Commission awarded on 22.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with completely resected NSCLC at high risk of recurrence after platinum-based chemotherapy whose tumours express PD-L1 in ≥ 50% of the tumour cells and who do not have EGFR mutations or ALK-positive NSCLC; adjuvant treatment
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-67 | Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-01-05 A G-BA decision was published.